Recent investigations suggested that IL-33 is a novel pro-fibrogenic cytokine in the development of SSc, mainly because it affects the TLR/NF-κB signaling pathways, and TGF-β1 expression is also regulated by IFN-γ. The gene discussed is IL33; the disease is systemic sclerosis.